The crypto market sees a general pullback, with the NFT sector leading the decline by nearly 4% and BTC falling below $80,000.
Foresight News reports, citing SoSoValue data, that the crypto market has generally pulled back, with the NFT sector leading the decline over the past 24 hours with a drop of 3.95%. Within the sector, Audiera (BEAT) rose by 6.27%, while ApeCoin (APE) fell by 4.64%. In addition, Bitcoin (BTC) dropped 1.93%, falling below $80,000; Ethereum (ETH) declined 1.23%, falling below $2,300.
In other sectors, the Meme sector fell 0.25% over 24 hours, with TROLL (TROLL) remaining relatively strong, rising 24.93%; the CeFi sector dropped 0.60%, with Cronos (CRO) down 5.54%; the PayFi sector declined by 1.69%, with Dash (DASH) down 6.84%; the Layer1 sector fell 2.15%, but Canton Network (CC) rose by 1.45%; the DeFi sector declined 3.16%, with LAB (LAB) surging 22.84%; the AI sector declined 3.57%, with Unibase (UB) spiking 32.63% intraday; the Layer2 sector dropped 3.60%, and zkSync (ZK) fell 8.37%. Crypto sector indices reflecting historical trends in the sectors show the ssiRWA, ssiAI, and ssiSocialFi indices fell by 9.26%, 9.25%, and 8.42%, respectively.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
